Date:7/26/2010

materially from those anticipated, including, without limitation, risks associated with: the success of current and future collaborative relationships; the market acceptance of our products; our ability to compete with larger, better financed pharmaceutical and biotechnology companies; new approaches to the treatment of our targeted diseases; our expectation of incurring continued losses; our uncertainty of product revenues and profits; our ability to generate future revenues; our ability to raise additional capital to continue our drug development programs; the success of our clinical trials; our ability to develop and commercialize products; our ability to obtain required regulatory approvals; our compliance with all Food and Drug Administration regulations; our ability to obtain; maintain and protect intellectual property rights for our products; the risk of litigation regarding our intellectual property rights; our limited sales and manufacturing capabilities; our dependence on third-party manufacturers and value added resellers; our ability to hire and retain skilled personnel; our volatile stock price; and other risks detailed in Repligen's annual report on Form 10-K on file with the Securities and Exchange Commission and the other reports that Repligen periodically files with the Securities and Exchange Commission. Actual results may differ materially from those Repligen contemplated by these forward-looking statements. These forward looking statements reflect management's current views and Repligen does not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date hereof except as required by law.

'/>"/>

SOURCE Repligen Corporation Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3
Related medicine technology :

1. Repligen Reports Notice of Allowance of a United States Patent Covering the Use of Uridine to Treat the Symptoms of Bipolar Disorder
2. Repligen Receives Notice of Allowance for Recombinant Protein A Patent
3. Repligen Announces Long Term Supply Agreement with GE Healthcare for Recombinant Protein A
4. Repligen Reports Phase 3 Clinical Trial Results of RG1068 in Pancreatic Imaging
5. Repligen Announces Plans to Initiate a Phase 2b Trial for RG2417 in Bipolar Disorder
6. Repligen Receives FDA Fast Track Designation for RG1068 for Pancreatic Imaging
7. Repligen Initiates Phase 3 Clinical Trial of RG1068 for Pancreatic MRI Imaging
8. Repligen Reports Positive Phase 2a Clinical Trial Results of RG2417 for Symptoms of Bipolar Disorder
9. Abviva Announces Notice of Canadian Patent for Technology Used in Breast Cancer Diagnostics and Therapeutics
10. Perrigo Announces FDA Approval for Over-the-Counter Cetirizine Cherry Syrup
11. QPS Announces the Acquisition of Xendo Drug Development